Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received October 8, 2014
- Accepted in final form January 13, 2015
- First Published February 26, 2015.
Author Disclosures
- Anders Svenningsson, MD,
- Joakim Bergman, MSc,
- Ann Dring, PhD,
- Mattias Vågberg, MD,
- Richard Birgander, MD,
- Thomas Lindqvist, MD,
- Jonathan Gilthorpe, PhD and
- Tommy Bergenheim, MD
- Anders Svenningsson, MD,
Served in advisory board for Sanofi-Genzyme and BiogenIdec
NONE
1. Travel and congress expenses paid for by BiogenIdec, Sanofi-Genzyme, Novartis and Baxter Medical 2. Speaker honoraria from BiogenIdec, Sanofi-Genzyme and Baxter
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Received non-conditional research grants from BiogenIdec
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joakim Bergman, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ann Dring, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Ume? university, post-doctoral researcher employed by Anders Svenningsson
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mattias Vågberg, MD,
NONE
NONE
(1)BiogenIdec, speaker honoriaria, (2)BiogenIdec, travel support to scientific meeting, (3)Novartis, travel support to scientific meeting, (4)Baxter Medical, travel support to scientific meeting, (5)Pharma Industry, writing honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)BiogenIdec
NONE
NONE
(1)Neuro Sweden
NONE
NONE
NONE
NONE
NONE
NONE
- Richard Birgander, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Thomas Lindqvist, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jonathan Gilthorpe, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tommy Bergenheim, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Swedish Cancer Society
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Pharmacology and Clinical Neuroscience (A.S., J.B., A.D., M.V., J.G., T.B.) and Department of Radiation Sciences (R.B., T.L.), Diagnostic Radiology, Umeå University, Sweden.
- Correspondence to Dr. Svenningsson: anders.svenningsson{at}neuro.umu.se
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Intrathecal treatment trial of rituximab in progressive MSAn open-label phase 1b studyJoakim Bergman, Joachim Burman, Jonathan D. Gilthorpe et al.Neurology, October 10, 2018 -
Article
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patientsTatiana Plavina, Kumar Kandadi Muralidharan, Geoffrey Kuesters et al.Neurology, September 15, 2017 -
Views & Reviews
Targeting B Cells to Modify MS, NMOSD, and MOGADPart 1Jonas Graf, Jan Mares, Michael Barnett et al.Neurology: Neuroimmunology & Neuroinflammation, December 16, 2020 -
Articles
Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MSF. Sellebjerg, L. Börnsen, M. Khademi et al.Neurology, December 07, 2009